Welcome to our dedicated page for Vicore Pharma Holding AB news (Ticker: VCRE), a resource for investors and traders seeking the latest updates and insights on Vicore Pharma Holding AB stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vicore Pharma Holding AB's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vicore Pharma Holding AB's position in the market.
Vicore Pharma (VCRE) will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24, 2026, from 8:30 to 8:55 AM ET.
The virtual event will feature a company presentation and 1×1 meetings with CEO Ahmed Mousa, CFO Hans Jeppsson and CMO Bernt van den Blink. Vicore focuses on angiotensin II type 2 receptor agonists, including its lead oral small molecule buloxibutid for idiopathic pulmonary fibrosis (IPF), which has Orphan Drug and Fast Track designations and is in a global 52‑week Phase 2b ASPIRE trial.
Vicore Pharma (NASDAQ:VCRE, STO:VICO) announced participation in two September 2026 healthcare conferences. At the Wells Fargo Healthcare Conference at Encore Boston Harbor in Boston, the company will hold 1×1 meetings on September 8 with CEO Ahmed Mousa. At the Cantor Global Healthcare Conference at the Waldorf Astoria New York, Mousa will join a fireside chat and 1×1 meetings on September 11 from 9:45–10:15 AM ET, which will be available via webcast.
Vicore Pharma (Nasdaq US:VCRE), a clinical-stage biopharmaceutical company focused on angiotensin II type 2 receptor agonists (ATRAGs), will present at the Pareto Securities 17th Annual Healthcare Conference at Hotel At Six in Stockholm.
The company’s CFO, Hans Jeppsson, is scheduled to present on Wednesday, September 2, 2026, from 14:25 to 14:45 CEST. Vicore’s lead program, buloxibutid, an oral ATRAG for idiopathic pulmonary fibrosis, holds FDA Orphan Drug and Fast Track designations and is being studied in the 52-week Phase 2b ASPIRE trial.
Vicore Pharma (NASDAQ:VCRE, Nasdaq Stockholm:VICO) will present at the European Respiratory Society (ERS) Congress 2026, held September 5–9 in Barcelona and online. The company will share new data on the design and baseline characteristics of patients in its global 52-week Phase 2b ASPIRE trial of buloxibutid in idiopathic pulmonary fibrosis (IPF), and translational findings on angiotensin II type 2 receptor activation in alveolar epithelial type II cells and MMP-13.
An oral presentation on ASPIRE-IPF is scheduled for September 7, 2026 at 11:35 CEST, and a poster on buloxibutid’s AT2 receptor activation and association with fibrosis resolution will be presented September 6, 2026 at 12:30 CEST. According to Vicore Pharma, ASPIRE completed enrollment in April 2026 with over 360 patients at more than 100 sites in 14 countries, enabling topline results in mid-2027. Presentation materials will be posted on the company’s website.
Vicore Pharma (NASDAQ:VCRE), a clinical-stage biopharmaceutical company developing angiotensin II type 2 receptor agonists (ATRAGs), will participate in the Leerink Therapeutics Forum.
The event will be held on Tuesday, July 14, 2026, at the Boston Harbor Hotel in Boston, Massachusetts, and will feature 1×1 investor meetings with CEO Ahmed Mousa.
Vicore Pharma (Nasdaq US:VCRE) will begin trading American Depositary Shares (ADSs) on the Nasdaq Capital Market on July 2, 2026. Each ADS represents 10 common shares.
The Nasdaq US listing is a secondary listing, adds no new shares, and aims to expand access to US capital markets.